BioMarin Pharmaceutical | BMRN - Selling And Administration Expenses


BioMarin Pharmaceutical reported $258.28M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 160.79M 14.06M Mar/2026
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
Alnylam Pharmaceuticals USD 347.92M 65.41M Jun/2026
Amgen USD 1.58B 354M Mar/2026
Bayer EUR 3.7B 356M Mar/2026
Biogen USD 709.7M 155.4M Jun/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Gilead Sciences USD 1.45B 326M Mar/2026
Incyte USD 351.73M 23.64M Jun/2026
Insmed USD 247.26M 34.78M Mar/2026
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
Moderna USD 216M 43M Jun/2026
Neurocrine Biosciences USD 383.1M 64.6M Jun/2026
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.49B 252M Mar/2026
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
United Therapeutics USD 156.6M 34M Mar/2026
Vertex Pharmaceuticals USD 582.2M 88.5M Jun/2026